Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial

Gut

Volumn 65, Issue 11, 2016, Pages 1784-1792

  Liou, Jyh Ming ^a   Chen, Chieh Chang ^a   Chang, Chi Yang ^b   Chen, Mei Jyh ^a   Chen, Chien Chuan ^a   Fang, Yu Jen ^a   Lee, Ji Yuh ^a   Yang, Tsung Hua ^a   Luo, Jiing Chyuan ^c   Wu, Jeng Yih ^d   Liou, Tai Cherng ^e   Chang, Wen Hsiung ^e   Hsu, Yao Chun ^b   Tseng, Cheng Hao ^b   Chang, Chun Chao ^f   Bair, Ming Jong ^e,g   Liu, Tzeng Ying ^h   Hsieh, Chun Fu ^h   Tsao, Feng Yun ^h   Shun, Chia Tung ^a   Lin, Jaw Town ^a,i   Lee, Yi Chia ^a,j   Wu, Ming Shiang ^a   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g MEIHO UNIVERSITY   (Taiwan)

^h Lienchiang County Government and Health Bureau of Lienchiang County   (Taiwan)

ⁱ FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^j NATIONAL TAIWAN UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE; METRONIDAZOLE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BLOATING; COMMUNITY POPULATION; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; CYP2C19 GENE; DIARRHEA; DISEASE ERADICATION; DIZZINESS; DNA POLYMORPHISM; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HELICOBACTER INFECTION; HOSPITAL POPULATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; TAIWAN; TASTE DISORDER; TREATMENT DURATION; UREA BREATH TEST; VOMITING; AMBULATORY CARE; BREATH ANALYSIS; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOSPITALIZATION; HUMANS; LANSOPRAZOLE; MALE; METRONIDAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84940930258     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310142     Document Type: Article

References (39)

1. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;12:CD008337.
2. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102: 1808-25.
3. Malfertheiner P, Megraud F, O'morain C, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
4. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
5. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
6. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31.
7. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7.
8. Liou JM, Chen CC, Chen MJ, et al, Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-13.
9. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14.
10. LeLorier J, Grégoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337: 536-42.
11. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.e3.
12. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174.
13. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013;62:676-82.
14. IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports 2014:No. 8). http://www.iarc.fr/en/publications/pdfsonline/wrk/wrk8/index.php
15. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
16. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol 2014;11:628-38.
17. Chen TS, Chang FY, Chen PC, et al. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol 2003;18:1237-43.
18. Lee MT, Chen CH, Chou CH, et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009;10:1905-13.
19. Liou JM, Chang CY, Sheng WH, et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacinand clarithromycin-based therapies. Antimicrob Agents Chemother 2011;55:1123-9.
20. Liou JM, Chen CC, Chang CY, et al, Taiwan Helicobacter Consortium. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013;68:450-6.
21. Maconi G, Parente F, Russo A, et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001;96:359-66.
22. Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014;8:21-8.
23. Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011;34: 1098-105.
24. Choi HS, Chun HJ, Park SH, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012;18: 2377-82.
25. Harmandar FA, Ustundag Y, Buyukuysal C, et al. The efficacy of clarithromycin based sequential therapy in eradication of Helicobacter pylori in Turkey. Gut 2012;61(Suppl 3):A443.
26. Wu GL, Lan Y, Zhang XJ. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication. World Chin J Dig 2011;19:3100-3.
27. Rakici H, Akdoǧan RA, Bedir R, et al. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. J Dig Dis 2014;15:508-13.
28. Sarikaya M, Dogan Z, Ergül B, et al. Functional dyspepsia symptom resolution after Helicobacter pylori eradication with two different regimens. Prz Gastroenterol 2014;9:49-52.
29. Nasa M, Choksey A, Phadke A, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study. Indian J Gastroenterol 2013;32:392-6.
30. Remes-Troche JM, Rivera GA, Ramos-De la Medina A, et al. M1119 Sequential Therapy vs. Standard Triple Therapy as Treatment of Helicobacter pylori Infection. A Prospective, Randomized, Parallel-Group, Open-Label Study in Mexico. Gastroenterology 2010;138:S-336.
31. Tang HL, Li Y, Hu YF, et al. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS ONE 2013;8:e62162.
32. Padol S, Yuan Y, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006;101:1467-75.
33. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322.
34. Liou JM, Chen CC, Chen MJ, et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011;66:1847-52.
35. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
36. Camargo MC, García A, Riquelme A, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014;109:485-95.
37. Rimbara E, Noguchi N, Kawai T, et al. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Helicobacter 2012;17:36-42.
38. Liou JM, Chang CY, Chen MJ, et al. The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors-A nationwide study. PLoS One 2015;10:e0124199.
39. Laws & Regulations. National Health Insurance Administration, Ministry of Health and Welfare, Taiwan R.O.C. http://www.nhi.gov.tw/webdata/webdata.aspx? menu=21&menu-id=713&webdata-id=2919